Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Licenses Max Planck Tech for Photon Detection

NEW YORK (GenomeWeb News) – PerkinElmer has licensed photon detection technology developed by the Max Planck Institute for use in a range of molecular imaging applications, the Waltham, Mass.-based company said today.

Under the exclusive agreement with Max Planck Innovation, the Max Planck Institute's technology transfer arm, the company has licensed solid state silicon photomultiplier, or SiPM, technology that it will use in clinical diagnostics, as well as molecular detection and analytical applications, the company said.

The SiPM technology, which was developed by scientists at the Max Planck Institute for Physics and the Moscow State Engineering Physics Institute, offers high photon detection efficiencies, short response time, and low power consumption, which makes it useful in a range of low light level applications, the company said.

PerkinElmer's VP and GM of global detection, Michael Ersoni, said in a statement that the new technology "shows promise for several important human and environmental health applications."

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.